M. J. WarrellK. G. NicholsonPornthep ChanthavanichAbha SinhaseniC. XuerefPravan SuntharasamaiD. A. WarrellChaisin ViravanRod PhanfungJ. C. Vincent-FalquetMahidol UniversityNuffield Department of Clinical MedicineThai Red Cross AgencyInstitut MerieuxMRC Clinical Research Centre2018-10-122018-10-121984-04-21The Lancet. Vol.323, No.8382 (1984), 874-876014067362-s2.0-0021253208https://repository.li.mahidol.ac.th/handle/20.500.14594/30664Neutralising antibody responses to six post-exposure regimens of human diploid cell strain rabies vaccine with or without human rabies immune globulin (HRIG) were studied in 98 patients. The total amount of vaccine used was 22-34% of that required by conventional regimens. Vaccine was given at multiple sites intradermally or subcutaneously with or without adjuvant. Antibody was detectable within 7 days of the first dose in all subjects only in the groups given 0·1 ml intradermally at 8 sites. From day 14 onwards all groups showed an excellent antibody response; there was little difference between the various regimens. Suppression of the response to 8-site intradermal vaccination by a large dose of HRIG could be prevented by giving the second dose of vaccine on day 7 rather than day 14. © 1984.Mahidol UniversityMedicineArticleSCOPUS10.1016/S0140-6736(84)91340-0